1Salven P, Teerenhovi L, Joensun H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in Non-Hodgkins lymphoma [J]. Blood, 1997;90:3167～3170. 被引量：1
2Salven P. Teerenhovi L, Joensun H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkins lymphoma [J]. Blood, 1999;94:3334～3340. 被引量：1
3Petri Salven, Arto Orpana, Lasse Teerenhovi. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients [J]. Blood, 2000;96:3712～3718. 被引量：1
4Maehara Y, Kabashima A, Koga T, et al. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma [J]. Sugery, 2000;128(3):408～16. 被引量：1
5Stefan A.M. Paul 1, Jonathan W. Simons 2, Nicola J. Mabjeesh 3 HIF at the crossroads between ischemia and carcinogenesis. Journal of Cellular Physiology, 2004;200(1):20～30. 被引量：1
6Bairey O, Zimra Y, Kagnovsky E, et al. Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Med Oncol, 2000;17(4):314～8. 被引量：1
7Wilson EA, Jobanputra S, Jackson R, et al. Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: [J]. Br J Haematol, 2002;119(1):128～30. 被引量：1
8Steven Brem, Sofia D. Cutting copper curbs angiogenesis [J]. National Cancer Institute, 2000;92(15):1202～1203. 被引量：1
9Easmon J. Copper and iron complexes with antitumour activity [J]. Ingenta, 2002;12(6):789～818?A. 被引量：1
10Bevacizumab (AvastinTM) Improves Survival in Metastatic Colorectal Cancer. http://www.nci.nib.gov/clinicaltrials/results/bevacizumab-and-colorectal-cancer0601. 被引量：1
4Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmye- loablative and myeloablative allogeneic hematopoietic cell trans- plantation for patients older than 50 years of age [ J 1. Blood, 2005,105(4) :1810-1814. 被引量：1
5Hari P, Carreras J, Zhang M J, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after re- duced-intensity compared to myeloablative conditioning E J 1. Biol Blood Marrow Transplant,2008, 14 (2) :236-245. 被引量：1
6Rodriguez R, Nademanee A, Ruel N, et al. Comparison of Re- duced-intensity and conventional myeloablative regimens for alloge- neie transplantation in non-Hodgkin' s lymphoma [ J ]. Biol Blood Marrow Transplant, 2006, 12 (12) : 1326-1334. 被引量：1
7Kim I, Lee KH, Choi Y, et al. Allogeneic stem cell transplanta- tion for patients with advanced hematological malignancies: com- parison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning E J]. J Korean Med Sci, 2007, 22: 227-234. 被引量：1
8Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or non- myeloablative conditioning and allogeneic hematopoietic cell trans- plantationl J ]. Biol Blood Marrow Transplant, 2008, 14 ( 5 ) : 538-545. 被引量：1
9Pifiana JL, Martino R, Gayoso J, et al. Reduced intensity condi- tioning HLA identical sibling donor allogeneie stem cell transplan- tation for patients with follicular lymphoma: long-term follow-up from two prospective muhicenter trials [ J ]. Haematologica, 2010, 95(7) :1176-82. 被引量：1
10Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent Non-Hodgkin' s lympboma[ J]. J Clin Oneol, 2008, 10;26(2) :211-217. 被引量：1
